B. Riley Securities Downgrades Bicycle Therapeutics to Neutral, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has downgraded Bicycle Therapeutics (NASDAQ:BCYC) from Buy to Neutral and lowered the price target from $33 to $28.
August 07, 2024 | 9:55 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B. Riley Securities downgraded Bicycle Therapeutics from Buy to Neutral and reduced the price target from $33 to $28.
The downgrade from Buy to Neutral and the reduction in the price target from $33 to $28 by B. Riley Securities is likely to negatively impact investor sentiment and the short-term stock price of Bicycle Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100